Sequential high-dose chemotherapy (SHDC) with autologous stem cell transplantation (ASCT) vs standard CHOP regimen for pts with untreated aggressive NHL. Result of the mistral trial from the Swiss Group for Clinical Cancer Research (SAKK)

Daniel Betticher, Susanne Cina(Swiss Group For Clinical Cancer Research), DC Linch(The Royal Free Hospital), John Radford(Manchester Academic Health Science Centre), R. Maibach, Ulrich Kaiser(University of Applied Sciences Landshut), Martin Kaufmann(Robert Bosch Hospital)

UCL Discovery (University College London)

June 1, 2005

Cited by 1

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.4k

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

|New England Journal of Medicine|2013|1.7k

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

|The Lancet Oncology|2021|428

Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

|Journal of Clinical Oncology|2005|421